Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Koltun

Showing results (401-410 of 423) with videos related to

Pageof 43
Sort By:
Cell Death & Disease|March 28, 2025
Role of the PI3K/AKT signaling pathway in the cellular response to Tumor Treating Fields (TTFields)Anat Klein-Goldberg, Tali Voloshin, Efrat Zemer Tov, et al.
Journal of Medicinal Chemistry|March 8, 2025
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted CancersJames Cregg, Anne V Edwards, Stephanie Chang, et al.
International Journal of Cancer|February 27, 2026
Efficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductal adenocarcinoma, with and without gemcitabine/nab-paclitaxelTal Kan, Tharwat Haj Khalil, Yiftah Barsheshet, et al.
Inflammatory Bowel Diseases|May 17, 2019
Challenges in IBD Research: Precision MedicineLee A Denson, Mark Curran, Dermot P B McGovern, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|June 12, 2025
Association of cardiorespiratory fitness with HR-pQCT bone parameters in older adults: the Study of Muscle, Mobility and Aging (SOMMA)Nina Z Heilmann, Kerri S Freeland, Reagan E Garcia, et al.
Bioorganic & Medicinal Chemistry Letters|December 20, 2017
Discovery of potent and selective inhibitors of calmodulin-dependent kinase II (CaMKII)Dmitry O Koltun, Eric Q Parkhill, Rao Kalla, et al.
Nature Cell Biology|August 15, 2018
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancersRobert J Nichols, Franziska Haderk, Carlos Stahlhut, et al.
Journal of Medicinal Chemistry|December 6, 2013
Two analogues of fenarimol show curative activity in an experimental model of Chagas diseaseMartine Keenan, Jason H Chaplin, Paul W Alexander, et al.
Cancer Discovery|June 22, 2026
Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-Type RAS Isoforms in Codon 13 RAS-Mutant CancersKyle J Seamon, Yongxian Zhuang, Yu Chi Yang, et al.
Journal of Medicinal Chemistry|April 14, 2012
Discovery and characterization of an inhibitor of glucosylceramide synthaseSteven Richards, Christopher J Larson, Elena S Koltun, et al.
Pageof 43

Showing results (401-410 of 423) with videos related to

Sort By:
Pageof 43
Cell Death & Disease|March 28, 2025
Role of the PI3K/AKT signaling pathway in the cellular response to Tumor Treating Fields (TTFields)Anat Klein-Goldberg, Tali Voloshin, Efrat Zemer Tov, et al.
Journal of Medicinal Chemistry|March 8, 2025
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted CancersJames Cregg, Anne V Edwards, Stephanie Chang, et al.
International Journal of Cancer|February 27, 2026
Efficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductal adenocarcinoma, with and without gemcitabine/nab-paclitaxelTal Kan, Tharwat Haj Khalil, Yiftah Barsheshet, et al.
Inflammatory Bowel Diseases|May 17, 2019
Challenges in IBD Research: Precision MedicineLee A Denson, Mark Curran, Dermot P B McGovern, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|June 12, 2025
Association of cardiorespiratory fitness with HR-pQCT bone parameters in older adults: the Study of Muscle, Mobility and Aging (SOMMA)Nina Z Heilmann, Kerri S Freeland, Reagan E Garcia, et al.
Bioorganic & Medicinal Chemistry Letters|December 20, 2017
Discovery of potent and selective inhibitors of calmodulin-dependent kinase II (CaMKII)Dmitry O Koltun, Eric Q Parkhill, Rao Kalla, et al.
Nature Cell Biology|August 15, 2018
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancersRobert J Nichols, Franziska Haderk, Carlos Stahlhut, et al.
Journal of Medicinal Chemistry|December 6, 2013
Two analogues of fenarimol show curative activity in an experimental model of Chagas diseaseMartine Keenan, Jason H Chaplin, Paul W Alexander, et al.
Cancer Discovery|June 22, 2026
Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-Type RAS Isoforms in Codon 13 RAS-Mutant CancersKyle J Seamon, Yongxian Zhuang, Yu Chi Yang, et al.
Journal of Medicinal Chemistry|April 14, 2012
Discovery and characterization of an inhibitor of glucosylceramide synthaseSteven Richards, Christopher J Larson, Elena S Koltun, et al.
Pageof 43